Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$398.7KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Cameron Reynolds
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 57
- Beta
- 1.09
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -53.13
Financials
Revenue
$398.7K+2231.9%Net Income
$-7.33MEBITDA
$-1.74MFree Cash Flow
$-5.16MEPS (diluted)
$-0.85Shares Outstanding (diluted)
9.15M+678.3%Operating Expenses
$4.55MCash & Debt
$2.79MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.73M | $-23.36M | $-4.40 |
| 2024 | $1.23M | $-26.97M | $-6.20 |
| 2023 | $775.3K | $-35.32M | $-10.00 |
| 2022 | $306.4K | $-30.27M | $-11.00 |
| 2021 | $90.0K | $-26.81M | $-10.20 |
| 2020 | $13.4K | $-20.35M | $-9.00 |
| 2019 | $17.1K | $-16.10M | $-8.20 |
| 2018 | $0.00 | $-18.01M | $-11.40 |
| 2017 | $0.00 | $-14.77M | $-11.20 |
| 2016 | $0.00 | $-11.91M | $-10.40 |
| 2015 | $0.00 | $-9.53M | $-10.80 |
| 2014 | $14.8K | $-8.21M | $-12.20 |
| 2013 | $0.00 | $-3.71M | $-6.80 |
| 2012 | $55.0K | $-4.08M | $-8.80 |
Valuation
VNRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (9)
- Newsprnewswire.com·19d ago·Neutral
VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ( XASE: VNRX ) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.
View source ↗ - Newsprnewswire.com·22d ago·Negative
…enior Secured Convertible Promissory Note Due May 20, 2027 Reduces Equity Overhang HENDERSON, Nev., Sept. 14, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind").
View source ↗ - Newsprnewswire.com·26d ago·Neutral
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference Targets $36 Billion TAM in Early Cancer Detection and MRD. HENDERSON, Nev.
View source ↗ - Newsbenzinga.com·40d ago·Neutral
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.
View source ↗ - Newsprnewswire.com·41d ago·Neutral
…n and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.
View source ↗ - Newsprnewswire.com·41d ago·Negative
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Nev.
View source ↗ - Newsseekingalpha.com·52d ago·Positive
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·55d ago·Neutral
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critical
View source ↗ - Newsprnewswire.com·55d ago·Neutral
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.38 per share
Typical surprise -31.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.85 vs $-0.57miss
- Thu, May 14$-0.97 vs $-0.70miss
- Tue, Mar 31$-1.05 vs $-0.80miss
- Thu, Nov 13$-1.00 vs $-0.80miss
- Thu, Aug 14$-1.20 vs $-1.00miss
- Thu, May 15$-1.20 vs $-0.86miss
Estimates and results for VNRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VNRX officers and directors.
- Bought
- $417k
- Sold
- —
12 trades
0 trades
- Reynolds Cameron Johnbought
- Reynolds Cameron Johnbought
- Reynolds Cameron Johnbought
- Innes Guy Archibaldbought
- Innes Guy Archibaldbought
- Still Timothy Ibought
- Still Timothy Ibought
- Reynolds Cameron Johnbought
88 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VNRX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.